GlassScriptPhysician profile
Robyn D Siperstein
NPI 1154422327
$753,636.77
in general payments reported to CMS, 2019-2025
22 companies · $69K in 2025
The $69K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $77K · 2021: $71K · 2022: $185K · 2023: $154K · 2024: $179K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $329K · Consulting Fee: $39K · Travel and Lodging: $27K · Food and Beverage: $6,329 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $329,360.80 |
| Consulting Fee | $38,535.42 |
| Travel and Lodging | $27,322.46 |
| Food and Beverage | $6,329.20 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339,207.51 | 2022-2025 | Botox, Kybella |
| Galderma Laboratories, L.P. | $210,460.91 | 2019-2025 | Dysport |
| Allergan, INC. | $203,068.10 | 2019-2022 | |
| Genzyme Corporation | $147.77 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.25 | 2023 | Sotyktu |
| Revance Therapeutics, INC. | $99.14 | 2024 | Daxxify |
| Janssen Biotech, INC. | $84.15 | 2022-2023 | Tremfya |
| Merz North America, INC. | $65.23 | 2024 | |
| Endo Pharmaceuticals INC. | $60.61 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $45.66 | 2021-2022 | |
| Dusa Pharmaceuticals, INC. | $39.84 | 2019 | |
| Verrica Pharmaceuticals INC. | $37.87 | 2023 | Ycanth |
| Novartis Pharmaceuticals Corporation | $37.16 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.42 | 2025 | Spevigo |
| Incyte Corporation | $25.67 | 2024 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $25.27 | 2019 | |
| Leo Pharma INC. | $23.20 | 2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $18.73 | 2021 | |
| Aclaris Therapeutics, INC. | $17.40 | 2019 | |
| Biofrontera INC. | $14.27 | 2019 | |
| Sensus Healthcare, INC. | $8.61 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Siperstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.